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Acute parvovirus B19 infection has been implicated in the pathogenesis of several
autoimmune conditions, including systemic lupus erythematosus. Viruses, including
human parvovirus B19, may trigger bouts of systemic lupus erythematosus in genetically
susceptible individuals. Herein, we report on two patients who developed systemic
lupus erythematosus associated with acute parvovirus B19 infection and discuss the
possible pathogenetic mechanisms implicated.
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Environmental factors, including viruses, along
with a genetic component, seem to play a major
role in the pathogenesis of autoimmune diseases
[1]. Systemic lupus erythematosus (SLE), an auto-
immune disease of unknown etiology, may be the
result of diverse pathogenetic mechanisms trig-
gered by different agents, including certain viruses
[2]. In fact, acute parvovirus B19 (pB19) infection
has been associated with SLE induction or exacer-
bation, suggesting that pB19 might be implicated
in the development of SLE [3–5].
We describe two cases of acute pB19 infection
associated with new-onset SLE and discuss the
relationship between viruses, particularly pB19,
autoimmunity and SLE.
CASE 1
An 18-year-old previously healthy man was
admitted because of arthralgia involving hands,
wrists, shoulders, knees and ankles of 1 month’s
duration. Physical examination was unremark-
able. The leukocyte count was 3.5 109/L, and
hemoglobin and platelet counts were within
normal limits. The erythrocyte sedimentation rate
(ESR) was 35mm/h, serum creatinine was 1.5mg/
dL, and the serum albumin level was 3.03 g/dL.
Urinalysis showed proteinuria of 14.3 g/day and
microhematuria. The titer of antinuclear antibodies
(ANAs) was >1/5120, with a speckled pattern,
anti-dsDNA >1/160, anti-ribouscleoprotein 1/50,
anticardiolipin IgM 13 MPL/mL (normal <12),
and IgG antibodies 62 GPL/mL (normal <24).
Rheumatoid factor, anti-Sm antigen, anti-Ro/La
antigens, antineutrophil cytoplasmic antibodies
and cryoglobulins were negative. Serum com-
plement levels were decreased. Serologic tests
for hepatitis B and C virus, cytomegalovirus,
Epstein–Barr virus, HIV, syphilis, Yersinia and
Brucella were negative. IgM antibodies against
parvovirus B19, measured by ELISA (Parvoscan-
B19 IgM, Euro-Diagnostica AB Ideon, Malmo¨,
Sweden) were positive. Radiographs of the chest
and involved joints and abdominal ultrasonogram
were normal. A renal biopsy showed diffuse pro-
liferative glomerulonephritis with deposits of IgM,
IgG, IgA and complement in mesangial, sube-
pithelial and subendothelial locations. With a
diagnosis of WHO class IV lupus nephritis, the
patient was treated with prednisone, 1mg/kg per
day, and cyclophosphamide, 6-month intravenous
pulses followed by 3-month pulses, with improve-
ment. Four months later, proteinuria, serum crea-
tinine and complement levels were normal. One
year after the ﬁrst determination, IgM antibodies
against pB19 were negative. Currently, ANA and
anti-dsDNA titer continue to be positive, and
serum complement levels are normal.
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CASE 2
A 27-year-old previously healthy woman reported
high fever and lumbar pain for 4 days before
admission. A presumptive diagnosis of acute pye-
lonephritis was made, and ciproﬂoxacin, 1 g/day,
was started. However, the patient’s condition
deteriorated on the following day, and she devel-
oped oral ulcers and a macular eruption involving
face and trunk. Physical examination was unre-
markable, apart from fever and the mucocuta-
neous lesions. The leukocyte count was 2.2
109/L, hemoglobin was 10.8 g/dL, platelet count
was 57 109/L, and ESR was 103mm/h. Serum
creatinine was normal. Urinalysis revealed many
red and white blood cells without proteinuria.
ANA at a titer of 1/640, anti-dsDNA 1/80, anti-
Sm >1/200, anti-RNP >1/200 and anticardiolipin
antibodies IgG 24GPL/mL were positive. Com-
plement levels were decreased. Direct Coomb, test
was positive for IgG and negative for complement.
Abdominal computed tomography revealed only
homogeneous hepatosplenomegaly. Chest radio-
graphs were unremarkable. Blood and urine cul-
tureswerenegative. Serologic tests against hepatitis
B and C virus, HIV, cytomegalovirus, Epstein–Barr
virus and syphilis were negative. IgM antibodies
to pB19 were positive. A skin biopsy showed a
chronic inﬂammatory perivascular inﬁltrate with-
out vasculitis. Immunoﬂuorescence was negative.
Bone marrow biopsy revealed erythroid hypopla-
sia. The patient was treated with antibiotics, with
slow improvement. However, 1 month after dis-
charge, the patient still had oral ulcers and com-
plained of loss of scalp hair. ANA, anti-dsDNA,
anti-Sm, anti-RNP and direct Coombs’ test contin-
ued to be positive. The leukocyte count was 3.9
109/L, hemoglobin was 10.8 g/dL, platelet count
was 257 109/L, and ESR was 30mm/h. Predni-
sone, 1mg/kg per day, was started. The symp-
toms rapidly disappeared, and blood cell counts
became normal. Two months later, IgM antibodies
against pB19were negative. Prednisonewas taper-
ed and ﬁnally stopped 10months after its onset.
Fourteen months after presentation, the patient is
asymptomatic,althoughanti-dsDNAantibodiesare
still positive and complement levels are decreased.
DISCUSSION
Autoimmunity results from an immune response
against autoantigens and represents a failure of
immunologic tolerance. The mechanisms under-
lying the onset of the autoimmune response are
undetermined. However, viral infections have
long been associated with the development of
autoimmune disorders [6]. Several mechanisms
have been proposed to explain how a viral infec-
tion can induce these disorders. Infection may
overcome immunologic tolerance by exposure of
cryptic epitopes of autoantigens to the immune
system and then activation of resting autoreactive
T-cells [7]. Another alternative mechanism, that of
molecular mimicry, consists of the induction of an
immune response against antigenic determinants
shared by the host and virus, which would result
in tissue injury [6].
Some authors [4,8] have suggested that pB19 is
able to induce a transient or chronic autoimmune
response. In addition, it is recognized that pB19
infection may trigger some clinical syndromes
with immunologic pathogenetic mechanisms [9].
Our two cases, as well as other reported cases of
pB19-induced SLE [3–5], suggest that this virus
may trigger mechanisms leading to an autoim-
mune response in the form of SLE. In addition,
our patients had anticardiolipin antibodies, and a
remarkable similarity in speciﬁcity of anticardio-
lipin antibodies has been found between pB19-
infected patients and SLE patients [10].
Although pB19 may trigger the development of
SLE, some authors have not found an increased
prevalence of pB19 infection in SLE patients in
relation to the general population [11]. However,
in another study [12], the presence of pB19 DNA
was detected in 24% of patients with SLE but in
none of those with other systemic rheumatic dis-
eases, and the prevalence of antibodies against
pB19 in SLE patients with detectable pB19 DNA
was lower than that of patients without pB19
DNA, suggesting that certain individuals with
chronic SLE are unable to mount an antibody
response to the virus. Clearance of the virus
may be impaired in these immunosuppressed
patients, and viral DNA could integrate into the
human chromosome, establishing latency [13],
which could have clinical consequences. In fact,
the association of immunocompromised patients
and autoimmune phenomena is well known.
Consequently, it could be speculated that treat-
ment for pB19 in SLE patients with this infection
might be useful to reduce ﬂare-ups of such a
serious disease, and administration of immuno-
globulins could be helpful to control infection if
116 Clinical Microbiology and Infection, Volume 8 Number 2, February 2002
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 115–117
discontinuation of the immunosuppressive ther-
apy is not feasible.
We believe that the possibility of acute pB19
infection should be considered in patients present-
ing with SLE features, and that a systematic search
for this infection in patients with new-onset SLE
should be carried out to delineate the pathogenetic
signiﬁcance of pB19 in this condition.
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